Holen Sie sich die Stockscreener-App
37.18
0.35%
-0.13
Handel nachbörslich:
37.10
-0.08
-0.22%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$37.31
Offen:
$37.43
24-Stunden-Volumen:
1.01M
Relative Volume:
0.59
Marktkapitalisierung:
$4.44B
Einnahmen:
$18.47M
Nettoeinkommen (Verlust:
$-589.53M
KGV:
-7.0684
EPS:
-5.26
Netto-Cashflow:
$-399.80M
1W Leistung:
-0.13%
1M Leistung:
+12.29%
6M Leistung:
-26.74%
1J Leistung:
-36.44%
1-Tages-Spanne:
$36.70
$38.16
1-Wochen-Bereich:
$36.70
$38.27
52-Wochen-Spanne:
$29.31
$61.38
Cytokinetics Inc Stock (CYTK) Company Profile
Firmenname
Cytokinetics Inc
Sektor
Branche
Telefon
(650) 624-3000
Adresse
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie CYTK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
37.18 | 4.46B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-24 | Eingeleitet | Barclays | Overweight |
| 2025-02-07 | Eingeleitet | Citigroup | Buy |
| 2025-01-22 | Eingeleitet | Stifel | Buy |
| 2024-11-08 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-13 | Herabstufung | Goldman | Buy → Neutral |
| 2024-01-24 | Herabstufung | UBS | Buy → Neutral |
| 2024-01-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-07 | Eingeleitet | B. Riley Securities | Buy |
| 2023-08-15 | Eingeleitet | SVB Securities | Outperform |
| 2023-02-17 | Eingeleitet | BofA Securities | Neutral |
| 2022-12-23 | Bestätigt | Needham | Buy |
| 2022-12-20 | Eingeleitet | Truist | Buy |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-01-28 | Eingeleitet | Goldman | Buy |
| 2021-12-22 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-10 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-03-12 | Eingeleitet | Wolfe Research | Outperform |
| 2021-02-18 | Eingeleitet | Barclays | Overweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-29 | Eingeleitet | Goldman | Neutral |
| 2020-07-10 | Eingeleitet | Raymond James | Strong Buy |
| 2020-05-05 | Eingeleitet | Mizuho | Buy |
| 2020-04-09 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-10 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2017-11-22 | Bestätigt | Morgan Stanley | Overweight |
| 2017-11-22 | Herabstufung | Needham | Strong Buy → Buy |
| 2017-11-21 | Bestätigt | H.C. Wainwright | Buy |
| 2017-07-31 | Eingeleitet | Morgan Stanley | Overweight |
| 2017-03-08 | Eingeleitet | Rodman & Renshaw | Buy |
| 2017-02-06 | Hochstufung | Needham | Buy → Strong Buy |
| 2016-12-16 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-07-28 | Bestätigt | Needham | Buy |
| 2015-11-10 | Bestätigt | FBR Capital | Outperform |
| 2015-11-09 | Bestätigt | ROTH Capital | Buy |
| 2015-07-24 | Bestätigt | MLV & Co | Buy |
| 2014-12-31 | Bestätigt | ROTH Capital | Buy |
| 2014-11-04 | Hochstufung | MLV & Co | Hold → Buy |
| 2014-04-28 | Bestätigt | Needham | Buy |
Alle ansehen
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics (CYTK): Is the FDA Delay a Buying Opportunity for Aficamten's Long-Term Payoff? - AInvest
Levi & Korsinsky Reminds Cytokinetics, Incorporated Investors of the Ongoing Investigation into Potential Violations of Securities LawsCYTK - ACCESS Newswire
Cytokinetics Incorporated Stock Analysis and ForecastSpectacular growth rates - PrintWeekIndia
Cytokinetics to Announce Second Quarter Results On August 7, 2025 - Yahoo Finance
What risks could impact Cytokinetics Incorporated stock performanceExceptional trading performance - jammulinksnews.com
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cytokinetics, Incorporated (CYTK) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Top Executive Sells Cytokinetics Stock in a Major Move - TipRanks
What drives Cytokinetics Incorporated stock priceRapid portfolio appreciation - Autocar Professional
What analysts say about Cytokinetics Incorporated stockFree Stock Market Knowledge Sharing - jammulinksnews.com
Piper Sandler Maintains a Buy Rating on Cytokinetics (CYTK) With a $107 PT - MSN
Is Cytokinetics Incorporated a good long term investmentOutstanding trading profits - jammulinksnews.com
Shareholders that lost money on Cytokinetics, Incorporated (CYTK) should contact Levi & Korsinsky about Securities Fraud InvestigationCYTK - ACCESS Newswire
Cytokinetics, Incorporated INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Cytokinetics, Incorporated (CYTK) - ACCESS Newswire
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cytokinetics’ Aficamten Study: A New Hope for Pediatric Heart Patients - TipRanks
Cytokinetics CEO Makes a Significant Stock Move! - TipRanks
Cytokinetics (CYTK) CEO Blum sells $190k in stock By Investing.com - Investing.com Nigeria
Cytokinetics (CYTK) CEO Blum sells $190k in stock - Investing.com India
Why Cytokinetics Incorporated stock attracts strong analyst attentionFree Stock Investment Discussion Area - Newser
What makes Cytokinetics Incorporated stock price move sharplyDaily Swing Candidates - Newser
CYTK ALERTLevi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025 - The Manila Times
Cytokinetics to Showcase Positive Aficamten Results for Obstructive Hypertrophic Cardiomyopathy at European Society of Cardiology Congress 2025 - Nasdaq
Cytokinetics(CYTK) Soars 6.93% on Analyst Optimism - AInvest
Cytokinetics, Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud AllegationsCYTK - ACCESS Newswire
Cytokinetics (CYTK): Balancing Optimism and Caution in Aficamten's High-Stakes Journey - AInvest
CYTK ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Cytokinetics, Incorporated Shareholders Who Lost Money - ACCESS Newswire
CYTK ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Cytokinetics, Incorporated - ACCESS Newswire
Cytokinetics Presents Positive Aficamten Data for Obstructive HCM at European Heart Failure Congress - Yahoo.co
11 Best Most Active Stocks To Buy According to Analysts - Insider Monkey
Cytokinetics Aligns U.S., Europe, and Japan—Could Global Synchronization Fuel Explosive Growth? - Smartkarma
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM - ScienceDirect.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Insider Sell Alert: Fady Malik Sells 2,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Ru - GuruFocus
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CYTK Stock News - GuruFocus
Cytokinetics Awards 140,000 Shares Worth $2.9M in Employee Inducement GrantsSee Exercise Price - Stock Titan
Finanzdaten der Cytokinetics Inc-Aktie (CYTK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cytokinetics Inc-Aktie (CYTK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | EVP Research & Development |
Jul 22 '25 |
Sale |
37.47 |
2,000 |
74,940 |
140,610 |
| Blum Robert I | President & CEO |
Jul 14 '25 |
Sale |
38.15 |
5,000 |
190,750 |
393,108 |
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):